Circulating endocannabinoids and affect regulation in human subjects

Coccaro, Emil F.; Hill, Matthew N.; Robinson, Lauren; Lee, Royce J.

doi:10.1016/j.psyneuen.2018.03.009

Cited by 31 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in a very recent study, the levels of circulating endocannabinoids were measured in subjects with and without history of psychiatric disorder and the relationships with categorically DSM-5 defined disorders or state dimensional measures of depression or anxiety were studied. Surprisingly, neither AEA nor 2-AG levels differed as a function of any syndromal/personality disorder and neither correlated significantly with state depression or state anxiety scores [115]. Therefore, we must be cautious since peripheral endocannabinoid levels may be not well correlated with brain concentrations.…”

Section: Endocannabinoid Levels In Anxietymentioning

confidence: 87%

The endocannabinoid system in mental disorders: Evidence from human brain studies

Ibarra-Lecue

Pilar-Cuéllar

Muguruza

et al. 2018

Biochemical Pharmacology

View full text Add to dashboard Cite

Mental disorders have a high prevalence compared with many other health conditions and are the leading cause of disability worldwide. Several studies performed in the last years support the involvement of the endocannabinoid system in the etiopathogenesis of different mental disorders. The present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. We will focus on the findings from human brain studies regarding alterations in endocannabinoid levels, cannabinoid receptors and endocannabinoid metabolizing enzymes in patients suffering mental disorders. Studies carried out in humans have consistently demonstrated that the endocannabinoid system is fundamental for emotional homeostasis and cognitive function. Thus, deregulation of the different elements that are part of the endocannabinoid system may contribute to the pathophysiology of several mental disorders. However, the results reported are controversial. In this sense, different alterations in gene and/or protein expression of CB1 receptors have been shown depending on the technical approach used or the brain region studied. Despite the current discrepancies regarding cannabinoid receptors changes in depression and schizophrenia, present findings point to the endocannabinoid system as a pivotal neuromodulatory pathway relevant in the pathophysiology of mental disorders.

show abstract

Section: Endocannabinoid Levels In Anxietymentioning

confidence: 87%

The endocannabinoid system in mental disorders: Evidence from human brain studies

Ibarra-Lecue

Pilar-Cuéllar

Muguruza

et al. 2018

Biochemical Pharmacology

View full text Add to dashboard Cite

show abstract

“…Over the last decade, the endocannabinoid system was extensively studied for its correlation with physical activity, which was recognized as a factor that notably modifies this essential biological system and its related molecular pathways [ 8 , 9 ]. Some recent studies demonstrated that plasma levels of endocannabinoids are notably higher after physical activity and might be associated with the long-term beneficial effects on neurophysiology, namely, mood, appetite, mental health, memory, as well as cognitive processes [ 10 , 11 , 12 ]. Interestingly, some studies indicate that physical activity significantly increases the expression of cannabinoid receptor CB1 (CB1R), a cannabinoid receptor that widely occurs in the striatum, and endocannabinoids, such as anandamide, which both might be correlated with the attenuation of neurological pathologies [ 10 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

Charytoniuk

Żywno

Konstantynowicz-Nowicka

et al. 2020

IJMS

View full text Add to dashboard Cite

The worldwide prevalence of neurological and neurodegenerative disorders, such as depression or Alzheimer’s disease, has spread extensively throughout the last decades, becoming an enormous health issue. Numerous data indicate a distinct correlation between the altered endocannabinoid signaling and different aspects of brain physiology, such as memory or neurogenesis. Moreover, the endocannabinoid system is widely regarded as a crucial factor in the development of neuropathologies. Thus, targeting those disorders via synthetic cannabinoids, as well as phytocannabinoids, becomes a widespread research issue. Over the last decade, the endocannabinoid system has been extensively studied for its correlation with physical activity. Recent data showed that physical activity correlates with elevated endocannabinoid serum concentrations and increased cannabinoid receptor type 1 (CB1R) expression in the brain, which results in positive neurological effects including antidepressant effect, ameliorated memory, neuroplasticity development, and reduced neuroinflammation. However, none of the prior reviews presented a comprehensive correlation between physical activity, the endocannabinoid system, and neuropathologies. Thus, our review provides a current state of knowledge of the endocannabinoid system, its action in physical activity, as well as neuropathologies and a possible correlation between all those fields. We believe that this might contribute to finding a new preventive and therapeutic approach to both neurological and neurodegenerative disorders.

show abstract

“…Several lines of evidence show that the endocannabinoid system influences a wide variety of neurobiological processes including emotionality, cognitive function, and glucocorticoid-mediated stress responses. This system is an attractive area for research into new pharmacotherapeutic targets for anxiety disorders (21). Studies show that both reductions (22) or elevations (23) in circulating endocannabinoid levels in patients diagnosed with post-traumatic stress disorder (PTSD), suggesting that dysregulated endocannabinoid signaling contributes to mental illnesses.…”

Section: Resultsmentioning

confidence: 99%

Endocrine, metabolic, and endocannabinoid alterations in rats exhibiting high anxiety-related behaviors

Vega-Torres

Kalyan-Masih

Argueta

et al. 2019

Preprint

View full text Add to dashboard Cite

Anxiety disorders are major risk factors for obesity. However, the mechanisms accounting for this susceptibility remain unclear. Animal models have proved to be useful tools for understanding the role of emotional functioning in the development and maintenance of metabolic alterations implicated in obesity. Here we sought to determine the predictive value of behavioral indices of anxiety for hormonal and metabolic imbalances in rats.Adult Lewis rats were screened on the elevated plus maze (EPM). K-means clustering was used to divide the rats into two groups based on their anxiety index in the EPM: low (LA) and high anxiety (HA) rats. This proxy of anxiety combines individual EPM parameters and accepted ratios into a single score. Four weeks later, we measured markers of endocrine and metabolic function. We found that relative LA rats, the HA rats exhibited reduced latencies to exit a modified light-dark conflict test. Our results show that the HA rats displayed increased corticosterone levels when compared to LA rats. Furthermore, the HA rats weighted more and exhibited an enhanced glycemic response to exogenously administered glucose during the glucose tolerance test, indicating glucose intolerance. Notably, when compared to LA rats, the HA rats showed higher circulating levels of the endogenous cannabinoid, 2-arachidonoyl-sn-glycerol (2-AG). Together, these data indicate that patterns of emotional reactivity associated with anxiety may share common pathological pathways with metabolic complications implicated in obesity.Uncovering metabolic risk factors for anxiety disorders have the potential to strongly impact how we treat mental illnesses. ObjectiveTo test the hypothesis that indices of anxiety in the elevated plus maze have predictive value for alterations implicated in obesity, which include heightened emotional reactivity, and dysregulated corticosterone, glucose metabolism, and circulating endocannabinoid levels.

show abstract

Circulating endocannabinoids and affect regulation in human subjects

Cited by 31 publications

References 34 publications

The endocannabinoid system in mental disorders: Evidence from human brain studies

The endocannabinoid system in mental disorders: Evidence from human brain studies

Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

Endocrine, metabolic, and endocannabinoid alterations in rats exhibiting high anxiety-related behaviors

Contact Info

Product

Resources

About